Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microba Life Sciences Limited ( (AU:MAP) ) just unveiled an update.
Microba Life Sciences Limited has announced it will release its Q2 FY26 Quarterly Activities Report, cash flow statement and investor presentation on 29 January 2026, alongside hosting a quarterly investor webinar presented by CEO Dr Luke Reid. The company is directing investors to its interactive Investor Hub for webinar registration, advance question submission and ongoing access to announcements, reflecting a push to deepen engagement with shareholders and improve transparency around its operational and financial performance.
The most recent analyst rating on (AU:MAP) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited is an Australian life sciences company focused on microbiome health and human care. It develops and delivers clinical-grade microbiome tests, leveraging world-leading science, data insights and collaboration tools to help people improve their health outcomes.
Average Trading Volume: 655,555
Technical Sentiment Signal: Hold
Current Market Cap: A$59.68M
Find detailed analytics on MAP stock on TipRanks’ Stock Analysis page.